Eli Lilly (LLY)

• Market cap: $658B
• 1 day: 2.48%
• 5 days: -2.49%
• 1 month: -3.16%
• 3 months: -14.46%
• 6 months: -1.73%
• Year to date: -5.76%
• 1 year: -6.83%
• 5 years: 360.52%
• 10 years: 905.88%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 47,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

142% more first-time investments, than exits

New positions opened: 475 | Existing positions closed: 196

6% more funds holding

Funds holding: 3,608 [Q3] → 3,816 (+208) [Q4]

4% more repeat investments, than reductions

Existing positions increased: 1,506 | Existing positions reduced: 1,451

0.14% more ownership

Funds ownership: 81.8% [Q3] → 81.94% (+0.14%) [Q4]

9% less call options, than puts

Call options by funds: $9.28B | Put options by funds: $10.1B

11% less capital invested

Capital invested by funds: $676B [Q3] → $604B (-$72.2B) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 463 [Q3] → 325 (-138) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $700 5% downside
• Avg. target: $966 32% upside
• High target: $1,124 53% upside

7 analyst ratings

• positive: 6 86%
• neutral: 0 0%
• negative: 1 14%

UBS Trung Huynh 42% 1-year accuracy 5 / 12 met price target	43% upside $1,050	Buy Maintained	2 May 2025
HSBC Rajesh Kumar 67% 1-year accuracy 2 / 3 met price target	5% downside $700	Reduce Downgraded	28 Apr 2025
Cantor Fitzgerald Carter Gould 26% 1-year accuracy 8 / 31 met price target	33% upside $975	Overweight Initiated	22 Apr 2025
Guggenheim Seamus Fernandez 36% 1-year accuracy 8 / 22 met price target	27% upside $928	Buy Maintained	14 Apr 2025
Morgan Stanley Terence Flynn 41% 1-year accuracy 9 / 22 met price target	53% upside $1,124	Overweight Maintained	9 Apr 2025